MGH Plans to Convert SNaPshot Genotyping Assay to NGS as First Step in Clinical NGS Strategy | GenomeWeb

Massachusetts General Hospital's Diagnostic Molecular Pathology Laboratory and Translational Research Laboratory are planning to implement next-generation sequencing for screening cancer patients.

As a first step, MGH researchers are converting their SNaPshot assay, a multiplex-PCR and CE-based test that screens for hotspot mutations in 14 oncogenes, to NGS. Later, they plan to develop larger panels for clinical use to guide treatment and placement into clinical trials, and also for research use to help identify markers of drug response and resistance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.